Catalog No.
Product Name
Application
Product Information
Citations
-
Stable Isotope
Dibucaine-d9 hydrochloride is a deuterium-labeled derivative of Dibucaine hydrochloride, primarily functioning as a sodium channel inhibitor. This compound exhibits strong inhibition of serum cholinesterase (SChE) activity, making it valuable in pharmacological studies related to analgesia and local anesthesia. Its stable isotope labeling facilitates advanced metabolic research and provides insights into drug metabolism and distribution. -
Cholinesterase (ChE) Inhibitor
Sinapine hydroxide is an acetylcholinesterase (AChE) inhibitor with significant potential in the investigation of neurodegenerative disorders such as Alzheimer's disease, myasthenia gravis, ataxia, and Parkinson's disease. This alkaloid, derived from cruciferous seeds, exhibits a range of biological activities including anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic, and radioprotective effects. Its ability to modulate cholinergic pathways makes it a valuable tool for studying cholinergic dysfunction and related therapeutic strategies. -
AChE/BuChE Inhibitor
Ipidacrine is a potent and selective inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), exhibiting IC50 values of 1 μM and 1.9 μM, respectively. This compound also acts as a partial agonist on M2-cholinergic receptors, promoting neuromuscular transmission and providing a moderate anti-pain effect. Ipidacrine is relevant for research into Alzheimer's disease, ischemic stroke, and diabetic complications, enhancing erectile function and exhibiting effects on ionic channels in neuronal membranes. Its applications extend to studying various deficits in central and peripheral cholinergic disorders. -
AChE/BuChE Inhibitor
Ipidacrine hydrochloride is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), with IC50 values of 1 μM and 1.9 μM, respectively. This compound also acts as a partial agonist at M2-cholinergic receptors and exhibits reversible cholinesterase inhibition. Ipidacrine hydrochloride facilitates neuromuscular transmission and demonstrates moderate analgesic properties. It shows promise in preclinical models for various conditions, including Alzheimer’s disease, ischemic stroke, facial nerve neuropathy, and diabetes-associated erectile dysfunction, highlighting its potential in investigating cholinergic system-related disorders. -
Sodium Channel Inhibitor
Dibucaine hydrochloride is a sodium channel inhibitor that effectively blocks the influx of sodium ions, thereby preventing the propagation of action potentials in excitable tissues. This compound exhibits potent activity as an anesthetic and is utilized in various research applications, including studies of nerve conduction and muscle excitability. Additionally, it serves as a significant inhibitor of serum cholinesterase, contributing to its utility in pharmacological investigations and the development of anesthetic protocols. -
μ-Opioid Receptor Agoinst/AChE Inhibitor
Eseroline is a potent μ-opioid receptor agonist and a selective, competitive inhibitor of acetylcholinesterase (AChE), with Ki values of 0.1 μM for AChE and 200 μM for butyrylcholinesterase (BuChE). This compound also acts as a nicotinic acetylcholine receptor allosteric enhancing ligand, enhancing acetylcholine signal transduction without directly activating the receptor. Eseroline's neurotoxic effects include cell membrane damage and energy metabolism disruption, making it a valuable tool for investigating Alzheimer's disease pathology and cholinergic signaling. -
BChE/NMDA/mAChR Antagonist
Ethopropazine hydrochloride is a potent and selective inhibitor of butyrylcholinesterase (BChE) and acts as a non-selective antagonist at muscarinic acetylcholine receptors (mAChR) and N-methyl-D-aspartate receptors (NMDA). This compound exhibits anticholinergic, antihistamine, and antiadrenergic activities, making it valuable in studying its effects on neuropathic pain conditions such as thermal hyperalgesia. Ethopropazine hydrochloride is particularly relevant in research related to Parkinson's disease, providing insights into cholinergic system modulation and receptor interactions. -
Aβ Inhibitor
Fustin (3,7,3',4'-Tetrahydroxyflavanone) is a potent inhibitor of amyloid β (Aβ), demonstrating significant effects on neurochemical markers associated with Alzheimer's disease. It enhances acetylcholine (ACh) levels and stimulates choline acetyltransferase (ChAT) activity while decreasing acetylcholinesterase (AChE) activity and expression. Additionally, Fustin promotes the expression of muscarinic M1 receptor genes and enhances receptor binding activity. This compound is valuable for research in Alzheimer's disease and neurodegenerative processes involving Aβ toxicity. -
Diacylglycerol Lipase Inhibitor
RHC 80267 is a potent and selective inhibitor of diacylglycerol lipase (DAGL), exhibiting an IC50 of 4 μM in canine platelets. This compound is valuable for research applications focusing on the modulation of lipid signaling pathways, particularly in the context of acetylcholine-induced relaxation. Additionally, RHC 80267 demonstrates inhibitory effects on cholinesterase with an IC50 of 4 μM and also inhibits cyclooxygenase (COX) and the hydrolysis of phosphatidylcholine (PC), making it a versatile tool for exploring lipid metabolism and neuronal signaling. -
M4 Receptor Antagonist
PCS1055 dihydrochloride is a selective and competitive antagonist of the muscarinic M4 receptor, with an IC50 value of 18.1 nM and a Kd of 5.72 nM. This compound effectively inhibits the binding of the radioligand [3H]-NMS to the M4 receptor, displaying a Ki of 6.5 nM. PCS1055 dihydrochloride demonstrates over 100-fold selectivity against M1, M3, and M5 receptors, and 30-fold selectivity at the M2 receptor. Additionally, it serves as a potent acetylcholinesterase inhibitor, with IC50 values of 22 nM and 120 nM for electric eel and human AChE, respectively, highlighting its potential for various neurological research applications. -
mAChR 4 Antagonist
PCS1055 is a selective competitive antagonist of the muscarinic M4 receptor, exhibiting an IC50 of 18.1 nM and a Kd of 5.72 nM. It effectively inhibits radioligand [3H]-NMS binding to the M4 receptor with a Ki of 6.5 nM. Additionally, PCS1055 demonstrates inhibitory activity against acetylcholinesterase (AChE), with IC50 values of 22 nM for electric eel AChE and 120 nM for human AChE. This compound is valuable for research focused on muscarinic receptor signaling and cholinergic modulation. -
AChE/mAChR Antagonist
CI-1002, a potent antagonist of acetylcholinesterase (AChE) and muscarinic acetylcholine receptors (mAChR), is utilized in neuroscience research. Its ability to inhibit AChE activity makes it particularly valuable for investigating the underlying mechanisms of cognitive dysfunction associated with Alzheimer’s disease. CI-1002 serves as a crucial tool for studying neurodegenerative processes and potential therapeutic strategies. -
Muscarinic M2 Acetylcholine Receptor Antagonist
Gallamine is a selective allosteric antagonist of the muscarinic M2 acetylcholine receptor, exhibiting an EC50 value of 130 nM in promoting the dissociation of [3H]NMS from porcine muscarinic M2 receptors. Additionally, it serves as an acetylcholinesterase inhibitor with varying IC50 values against different isoforms: 1070 μM for EeAChE, 1480 μM for hAChE, and 235 μM for hBChE. Gallamine is known to elevate levels of free norepinephrine and is utilized in research exploring muscle relaxation and pharmacological modulation of cholinergic signaling. -
Pro-cholinergic Agent
Deanol pidolate is an orally active pro-cholinergic agent that enhances cognitive function by promoting the release of acetylcholine (ACh), while minimizing the side effects commonly associated with cholinesterase inhibitors. It has demonstrated the ability to mitigate the negative impacts of scopolamine on long-term memory, facilitating a quicker recovery to baseline memory performance. Deanol pidolate is particularly useful in research applications related to Alzheimer's disease and other cognitive disorders. -
Stable Isotope
Itopride-d6 hydrochloride is a deuterium-labeled derivative of Itopride hydrochloride that serves as a stable isotope. Itopride functions as a gastroprokinetic agent by inhibiting acetylcholinesterase (AChE) and antagonizing dopamine D2 receptors. This compound is valuable for studies investigating gastrointestinal motility and neurotransmitter interactions, as well as for tracing and quantifying its metabolic pathways in biological research. -
Acetylcholinesterase Inhibitor
Trimethylammonium chloride is a non-competitive inhibitor of acetylcholinesterase, targeting the enzymatic activity responsible for the hydrolysis of the neurotransmitter acetylcholine. By reversibly blocking the deacetylation process of acetylcholinesterase, this reagent plays a critical role in studies related to neurobiology and the modulation of synaptic transmission. Its application extends to research investigating cholinergic signaling pathways and potential therapeutic strategies for neurological disorders. -
Stable Isotope
(Z)-Tetrachlorvinphos-d6 is a deuterated form of Tetrachlorvinphos, an organophosphorus pesticide that primarily acts as a cholinesterase inhibitor. This stable isotope is utilized in research to trace metabolic pathways and analyze pesticide residues in various biological matrices. With low toxicity to mammals, it provides a safe and useful tool for studying the environmental impact and biochemical interactions of pesticide application. -
Endogenous Metabolite
Bendiocarb is a carbamate compound that primarily acts as an inhibitor of the enzyme acetylcholinesterase. This inhibition results in increased levels of acetylcholine, which plays a crucial role in neurotransmission and muscle contraction. Bendiocarb is utilized in research applications focusing on neurobiology and the study of cholinergic systems, as well as in the examination of potential neurotoxic effects. -
Endogenous Metabolite
Neostigmine iodide is a reversible inhibitor of acetylcholinesterase, enhancing muscle tone and function. This compound is primarily utilized in the management of myasthenia gravis, aiming to improve muscle strength in affected patients. Additionally, Neostigmine iodide is employed in anesthetic procedures to counteract the effects of nondepolarizing muscle relaxants, such as rocuronium, thereby facilitating recovery from anesthesia. -
Endogenous Metabolite
BuChE-IN-14 is a selective inhibitor of acetylcholinesterase (AChE), primarily targeting endogenous metabolite pathways. In vitro studies demonstrated a concentration-dependent inhibition of AChE activity in rat brain tissue, leading to increased extracellular acetylcholine (ACh) levels in the hippocampus and striatum. This compound shows potential for addressing memory impairments linked to cholinergic dysfunction, making it valuable for research into neurodegenerative diseases and cognitive enhancement. -
Cholinesterase (ChE) Inhibitor
Vomifoliol is a cholinesterase (ChE) inhibitor that exhibits significant antiacetylcholinesterase activity, comparable to that of abscisic acid (ABA). Additionally, this compound shows moderate antileishmanial activity, making it a valuable tool for research into neurodegenerative disorders and parasitic infections. Its unique structure, featuring a modified 2,4-pentadiene side chain, further contributes to its biological activity, offering potential applications in pharmacological studies. -
Aβ1-42 Aggregation Inhibitor
Aβ1–42 aggregation inhibitor 1 is a potent inhibitor of Aβ1-42 aggregation, targeting its self-mediated aggregation pathway. This compound effectively inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values of 2.64 μM and 1.29 μM, respectively. At a concentration of 25 μM, it reduces Aβ1-42 aggregation by 51.29%. Aβ1–42 aggregation inhibitor 1 is suitable for research applications focused on the mechanisms of Alzheimer's disease and potential therapeutic interventions. -
AChE Inhibitor
Phenserine is a potent, noncompetitive inhibitor of acetylcholinesterase (AChE), derived from Physostigmine. It selectively targets AChE and has been shown to reduce the formation of β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ). This compound is primarily utilized in research related to cognitive function and the progression of Alzheimer's disease, demonstrating potential therapeutic benefits in enhancing cognitive performance. -
AChE Inhibitor
Buntanetap L-Tartrate is a selective acetylcholinesterase (AChE) inhibitor with an IC50 of 22.2 nM. This compound functions as a neurotoxic protein translation inhibitor, targeting proteins such as amyloid precursor protein (APP), α-synuclein (αSYN), and huntingtin protein (HTT). By obstructing the mRNA translation of β-amyloid precursor protein, Buntanetap reduces its production and exhibits anti-inflammatory properties. Its applications include research related to Alzheimer's disease and Parkinson's disease. -
β-amyloid Aggregation Inhibitor
Methyl tridecanoate is a β-amyloid aggregation inhibitor that demonstrates a moderate capacity to impede the formation of β-amyloid fibrils, which are implicated in neurodegenerative diseases such as Alzheimer's. Additionally, this compound displays weak inhibition of acetylcholinesterase (AChE), an enzyme involved in cholinergic neurotransmission. Its dual activity suggests potential applications in research focused on Alzheimer's pathology and related cognitive disorders. -
Stable Isotope
Protriptyline-d3 is a deuterated analog of the tricyclic antidepressant Protriptyline, serving as a stable isotope for research applications. It exerts potent inhibition of acetylcholinesterase (AChE) with an IC50 value of 0.06 mM and effectively inhibits amyloid beta (Aβ) self-assembly. This compound is valuable for studying the mechanisms underlying depression and Alzheimer's disease. -
NF-κB Activator
Methylchloroisothiazolinone is a potent NF-κB activator known for its pro-inflammatory properties. It induces the expression of pro-inflammatory cytokines, including IL-1β, TNF-α, and IL-6, through the activation of the NF-κB signaling pathway and upregulation of TLR4. This compound is utilized in research focusing on allergic contact dermatitis and immunotoxicity mechanisms. Additionally, Methylchloroisothiazolinone demonstrates neurotoxic effects and has been shown to impair cholinesterase activity, leading to increased oxidative stress and detrimental impacts on aquatic organisms, specifically Mediterranean mussels. -
NF-κB Inhibitor
6-O-p-Hydroxybenzoylglutinoside is a selective NF-κB inhibitor that effectively suppresses TNF-α-activated NF-κB transcriptional activity, with an IC50 of 52.78 μM. This compound demonstrates targeted biological activity without significantly inhibiting soluble epoxide hydrolase (sEH), acetylcholinesterase (AChE), or butyrylcholinesterase (BChE). Isolated from the seeds of Catalpa bungei (Manchurian catalpa), 6-O-p-Hydroxybenzoylglutinoside is valuable for research applications focused on inflammation and signal transduction pathways. -
Aβ Aggregation Inhibitor
Aβ-IN-5 is a potent Aβ aggregation inhibitor, demonstrating oral bioavailability. It effectively inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values of 21.29 μM and 1.32 μM, respectively. This compound exhibits significant neuroprotective effects while maintaining low neurotoxicity, making it a valuable tool for research on neurodegenerative diseases, particularly Alzheimer’s disease. -
Cholinesterase (ChE) Inhibitor
hAChE/Aβ1-42-IN-1 is a potent cholinesterase (ChE) inhibitor that effectively inhibits human acetylcholinesterase (hAChE) and prevents the aggregation of Aβ1-42 peptides. This compound demonstrates favorable relative safety in HepG2 cell lines and exhibits excellent blood-brain barrier (BBB) penetration, exhibiting a wide safety margin. hAChE/Aβ1-42-IN-1 is a valuable tool for research focusing on Alzheimer's disease (AD) and related neurodegenerative conditions. -
Antidepressant Agent
Protriptyline is a potent tricyclic antidepressant (TCA) primarily targeting neurotransmitter reuptake mechanisms. It exhibits significant inhibition of acetylcholinesterase (AChE) activity, with an IC50 value of 0.06 mM, and effectively disrupts Aβ self-assembly. This compound is utilized in research focused on depression and Alzheimer’s disease, providing insights into therapeutic strategies for these conditions. -
BuChE Inhibitor
BuChE-IN-6 is a potent and selective inhibitor of butyrylcholinesterase (BuChE), exhibiting IC50 values of 0.46 μM and 0.51 μM for equine and human BuChE, respectively. This compound also demonstrates the ability to inhibit self-aggregation of amyloid-beta 42 (Aβ42), making it a valuable tool for research related to neurodegenerative diseases. Its unique properties support investigations into cholinergic dysfunction and the pathogenesis of Alzheimer's disease. -
hAChE/hBACE Inhibitor
hAChE/hBACE-1-IN-4 is a quinazoline derivative that functions as a dual inhibitor of human acetylcholinesterase (hAChE) and human β-site amyloid precursor protein cleaving enzyme 1 (hBACE-1). It exhibits potent inhibitory activity with IC50 values of 0.283 μM for hAChE and 0.231 μM for hBACE-1. This compound demonstrates the ability to inhibit amyloid-beta (Aβ) aggregation and shows favorable properties such as non-neurotoxicity, blood-brain barrier permeability, and oral bioavailability. hAChE/hBACE-1-IN-4 is suitable for research applications related to Alzheimer's disease. -
AChE Inhibitor
AChE-IN-19 is a potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 0.56 μM. This compound also demonstrates the ability to inhibit amyloid beta (Aβ) aggregation, contributing to its neuroprotective properties. AChE-IN-19 has been shown to exert minimal toxicity on SH-SY5Y neuronal cells, making it a valuable tool for research applications related to Alzheimer's disease. -
Amyloid-β Inhibitor
AChE/Aβ-IN-5 is a bifunctional inhibitor that targets acetylcholinesterase (AChE) and reduces the auto-induced aggregation of amyloid-β (Aβ) peptides. This compound has demonstrated the ability to significantly ameliorate cognitive deficits induced by scopolamine and Aβ in murine models. It serves as a valuable tool for research into neurodegenerative diseases, particularly Alzheimer's disease, by providing insights into the mechanisms underlying cognitive impairment. -
AChE Inhibitor
Memoquin is an AChE inhibitor with significant anti-amyloid and antioxidant properties. It exhibits oral bioavailability and selectively inhibits BACE-1 and AChE, with IC50 values of 108 nM and 1.55 nM, respectively. Memoquin is noted for its ability to enhance cognitive function while preventing Aβ-induced neurotoxicity associated with oxidative stress. This compound is valuable for research into Alzheimer's disease and related neurodegenerative disorders. -
AChE Inhibitor
Phenserine tartrate is a selective, noncompetitive inhibitor of acetylcholinesterase (AChE) derived from Physostigmine. This compound has been shown to reduce the formation of β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ), key factors involved in Alzheimer's disease pathology. Phenserine tartrate has demonstrated potential in improving cognitive performance and may help slow the progression of Alzheimer's disease, making it a valuable tool for research in neurodegenerative disorders. -
ChE/Aβ1-42 Aggregation Inhibitor
ChE/Aβ1-42-IN-1 is a potent inhibitor of acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and amyloid-beta peptide (Aβ1-42) aggregation, exhibiting IC50 values of 0.062 µM, 0.767 µM, and 1.227 µM, respectively. This compound demonstrates significant blood-brain barrier (BBB) penetration, making it a promising candidate for research into Alzheimer's disease. ChE/Aβ1-42-IN-1's multi-targeted mechanism positions it as a valuable tool for studying therapeutic strategies in neurodegenerative disorders. -
AChE Inhibitor
hAChE-IN-10 is a potent inhibitor of human acetylcholinesterase (AChE), demonstrating an IC50 of 6.34 nM. This compound exhibits significant antioxidant properties and effectively scavenges free radicals. Additionally, hAChE-IN-10 has been shown to inhibit Cu2+-induced aggregation of Aβ1-42, reduce amyloid plaque formation, and provide neuroprotective effects. It has also been linked to the improvement of cognitive deficits in mouse models induced by scopolamine, making it a valuable tool for studying neurodegenerative diseases and cognitive impairment. -
MAO-B Inhibitor
MAO-B-IN-50 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 value of 0.06 μM. This compound is effective in inhibiting the aggregation of amyloid-beta (Aβ40/42) and Tau proteins, with overall IC50 values near 1 μM. Additionally, MAO-B-IN-50 shows potent selective inhibition of acetylcholinesterase (AChE) with an IC50 of 1.78 μM. It is suitable for use in research related to Alzheimer's disease. -
AChE Inhibitor
AChE-IN-12 is a selective acetylcholinesterase (AChE) inhibitor that effectively penetrates the blood-brain barrier, exhibiting IC50 values of 0.41 μM for rat AChE and 1.88 μM for electric eel AChE. This compound also demonstrates antioxidant properties (ORAC = 3.3 eq), selectively chelates metals, and inhibits human monoamine oxidase B (MAO-B) with an IC50 of 8.8 μM. AChE-IN-12 significantly inhibits both self- and Cu2+-induced aggregation of Aβ1-42 and displays neuroprotective effects, making it a valuable tool for research related to Alzheimer’s disease. -
AChE/BuChE Inhibitor
AChE/BuChE-IN-3 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), exhibiting IC50 values of 0.65 μM and 5.77 μM, respectively. This compound effectively inhibits the aggregation of amyloid beta peptide Aβ1-42 and demonstrates neuroprotective properties with minimal toxicity in SH-SY5Y cells. AChE/BuChE-IN-3 is suitable for research applications related to Alzheimer's disease, providing insight into cholinergic system modulation and potential therapeutic strategies. -
Aβ1-42/AChE Inhibitor
AChE-IN-59 is a potent acetylcholinesterase (AChE) inhibitor, displaying an IC50 value of 0.05 μM. This compound effectively inhibits the aggregation of amyloid-beta peptide Aβ1-42, offering protective effects on neuronal cells and demonstrating favorable penetration of the blood-brain barrier. AChE-IN-59 is a valuable tool for research focused on Alzheimer's disease and related neurodegenerative disorders. -
AChE Inhibitor
AP2238 is a dual-function acetylcholinesterase (AChE) inhibitor that demonstrates Ki values of 21.7 μM for human AChE and 48.9 μM for butyrylcholinesterase (BuChE). This compound effectively inhibits the pro-fibrotic interaction between the peripheral site of AChE and amyloid-beta (Aβ), as well as Aβ aggregation. AP2238 is primarily utilized in Alzheimer's disease research, contributing to studies focused on neurodegeneration and cholinergic dysfunction. -
AChE/BuChE Inhibitor
AChE/BuChE-IN-2 is a selective inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), demonstrating IC50 values of 0.72 μM and 0.16 μM, respectively. This compound exhibits non-competitive inhibition of AChE and effectively inhibits β-amyloid (Aβ) aggregation, with an IC50 of 62.52 μM. Notably, AChE/BuChE-IN-2 is capable of crossing the blood-brain barrier, making it a valuable tool for studying neurodegenerative conditions, such as Alzheimer's disease. -
BuChE Inhibitor
Multitarget AD inhibitor-1 is a selective and reversible inhibitor of butyrylcholinesterase (BuChE), exhibiting IC50 values of 7.22 μM for human BuChE and 1.55 μM for equine BuChE. This compound also inhibits β-secretase activity (IC50 = 41.60 μM) and demonstrates a strong capacity to inhibit amyloid β aggregation (IC50 = 3.09 μM) as well as tau aggregation. As a diphenylpropylamine derivative, it holds promise for multifunctional disease-modifying applications in Alzheimer’s research. -
AChE Inhibitor
hAChE-IN-3 is a potent acetylcholinesterase (AChE) inhibitor with demonstrated blood-brain barrier permeability. It exhibits significant inhibitory effects against butyrylcholinesterase (BuChE), monoamine oxidase B (MAO-B), and β-site amyloid precursor protein cleaving enzyme 1 (BACE-1), with IC50 values of 0.44, 0.08, 5.15, and 0.38 μM, respectively. Additionally, hAChE-IN-3 possesses antioxidant properties and metal chelating ability, enabling it to interact with peripheral anion sites and influence β-amyloid accumulation. This compound holds promise for advancing research in Alzheimer's disease and related neurodegenerative disorders. -
Multi-target Inhibitor
AChE-IN-63 is a multi-target inhibitor with a primary action as a selective inhibitor of human acetylcholinesterase (hAChE), exhibiting an IC50 of 0.103 μM. This compound also demonstrates inhibitory activity against human butyrylcholinesterase (hBChE) and human beta-site amyloid precursor protein cleaving enzyme 1 (hBACE-1) with IC50 values of 10 μM and 1.342 μM, respectively. AChE-IN-63 effectively inhibits Aβ aggregation, thereby preventing the formation and deposition of Aβ1-42. Due to its ability to penetrate the blood-brain barrier and oral bioavailability, it is primarily utilized in research related to Alzheimer's disease. -
BChE Inhibitor
BChE-IN-8 is a potent and orally active inhibitor of butyrylcholinesterase (BChE), demonstrating IC50 values of 0.15 nM against equine serum BChE and 45.2 nM against human BChE. Its high stability ensures enhanced blood concentration and tissue exposure. BChE-IN-8 exhibits neuroprotective and cognitive-enhancing effects through modulation of the cholinergic system, amyloid beta (Aβ) aggregation, and neuropeptide levels. This compound is particularly relevant for research into Alzheimer's disease. -
AChE/MAO-B Inhibitor
AChE/MAO-B-IN-9 is a selective, reversible, non-competitive inhibitor of acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B), exhibiting an IC50 of 0.156 μM against electric eel AChE. This compound effectively inhibits the formation of Aβ40/42 fibrils, promotes the depolymerization of Aβ fibrils, and suppresses Tau protein fibril formation. Additionally, AChE/MAO-B-IN-9 demonstrates antioxidant and neuroprotective properties, while alleviating memory deficits induced by scopolamine in murine models. This reagent is valuable for research related to Alzheimer’s disease.
